Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
Adrenal Cortex Hormones/administration & dosage/adverse effects; Adult; Anti-Inflammatory Agents/administration & dosage/adverse effects/blood; Biomarkers/blood; Crohn Disease/blood/diagnosis/drug therapy/immunology; Double-Blind Method; Drug Dosage Calculations; Drug Monitoring; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Europe; Female; Gastrointestinal Agents/administration & dosage/adverse effects/blood; Humans; Infliximab/administration & dosage/adverse effects/blood; Male; Predictive Value of Tests; Proof of Concept Study; Prospective Studies; Remission Induction; Time Factors; Treatment Outcome; Young Adult; Crohn's Disease; Infliximab; Mucosal Healing; Therapeutic Drug Monitoring
Abstract :
[en] BACKGROUND & AIMS: A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their serum concentrations of these drugs are above a determined therapeutic threshold. We performed a prospective, randomized trial to determine whether therapeutic drug monitoring (TDM) to maintain serum levels of infliximab above 3 mug/mL produced higher rates of clinical and endoscopic remission than adapting dose based only on symptoms. METHODS: We performed a double-blind trial in which 122 biologic-naive adult patients with active CD (71 female, median age 29.8 years) received induction treatment with infliximab in combination with an immunosuppressant, from July 2012 through September 2015 at 27 centers in Europe. At week 14 of treatment, patients were randomly assigned (1:1:1) to 3 infliximab maintenance groups: dose increases (2 maximum) in steps of 2.5 mg/kg based on clinical symptoms and biomarker analysis and/or serum infliximab concentrations (dose intensification strategy [DIS]1 group); dose increase from 5 to 10 mg/kg based on the same criteria (DIS2 group); dose increase to 10 mg/kg based on clinical symptoms alone (controls). Patients' CD activity index scores, levels of C-reactive protein, fecal levels of calprotectin, and serum concentrations of infliximab were determined at baseline and at weeks 2, 4, 6, 12, and 14 of treatment, and then every 4 weeks thereafter until week 54. The primary endpoint was sustained corticosteroid-free clinical remission (CD activity index <150) from weeks 22 through 54 with no ulcers at week 54. RESULTS: The primary endpoint was reached by 15 (33%) of 45 patients in the DIS1 group, 10 (27%) of 37 patients in the DIS2 group, and 16 (40%) of 40 patients in the control group (P = .50). CONCLUSIONS: In a prospective randomized exploratory trial of patients with active CD, we found increasing dose of infliximab based on a combination of symptoms, biomarkers, and serum drug concentrations does not lead to corticosteroid-free clinical remission in a larger proportion of patients than increasing dose based on symptoms alone. EUDRACT NUMBER: 2011-003038-14.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
D'Haens, Geert
Vermeire, Severine
Lambrecht, Guy
Baert, Filip
Bossuyt, Peter
Pariente, Benjamin
Buisson, Anthony
Bouhnik, Yoram
Filippi, Jerome
Vander Woude, Janneke
Van Hootegem, Philippe
Moreau, Jacques
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
Colombel, J.F., Sandborn, W.J., Reinisch, W., et al., SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 (2010), 1383–1395.
Colombel, J.F., Rutgeerts, P., Sandborn, W.J., et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 12 (2014), 414–422.
D'Haens, G., Baert, F., van Assche, G., et al. Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008), 660–667.
Rutgeerts, P., Diamond, R.H., Bala, M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 63 (2006), 433–442.
Shah, S.C., Colombel, J.F., Sands, B.E., et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther 43 (2016), 317–333.
Maser, E.A., Villela, R., Silverberg, M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 4 (2006), 1248–1254.
Paul, S., Del Tedesco, E., Marotte, H., et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 19 (2013), 2568–2576.
Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., et al., ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002), 1541–1549.
Cornillie, F., Hanauer, S.B., Diamond, R.H., et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 63 (2014), 1721–1727.
Steenholdt, C., Brynskov, J., Thomsen, O.Ø., et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 63 (2014), 919–927.
Vande Casteele, N., Ferrante, M., Van Assche, G., et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148 (2015), 1320–1329.
Gisbert, J.P., Panes, J., Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 104 (2009), 760–767.
Vande Casteele, N., Buurman, D.J., Sturkenboom, M.G., et al. Detection of infliximab concentrations and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 36 (2012), 765–771.
Mary, J.Y., Modigliani, R., Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30 (1989), 983–989.
D'Haens, G., Van Deventer, S., Van Hogezand, R., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116 (1999), 1029–1034.
Colombel, J.F., Panaccione, R., Bossuyt, P., et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 17 (2017), 32641–32647.
Schnitzler, F., Fidder, H., Ferrante, M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58 (2009), 492–500.
Bortlik, M., Duricova, D., Malickova, K., et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 7 (2013), 736–743.
Drobne, D., Bossuyt, P., Breynaert, C., et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. Clin Gastroenterol Hepatol 13 (2015), 514–521.
Roblin, X., Boschetti, G., Duru, G., et al. Distinct thresholds of infliximab trough level are associated with different therapeutic outcomes in patients with inflammatory bowel disease: a prospective observational study. Inflamm Bowel Dis 23 (2017), 2048–2053.
Drobne, D., Kurent, T., Golob, S., et al. Infliximab trough levels above 7 mg/ml in inflammatory bowel disease treated with infliximab: better control of inflammation without increased risk of infection. Oral communication at UEGW, 2017 Barcelona (OP221). Presented at the European Crohn's and colitis organization, Amsterdam, March 2016 and the Digestive Disease Week, San Diego, CA, May 2016.
Brandse, J.F., Mathôt, R.A., van der Kleij, D., et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 14 (2016), 251–258.
Rodriguez-Rodriguez, L., Leon, L., Lamas, J.R., et al. Dose down-titration of biological DMARDs in patients with rheumatoid arthritis over time and in daily clinical practice. Clin Exp Rheumatol 34 (2016), 872–879.
